Kopran ltd share price

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958 and is headquartered in Mumbai, India. Technical Analysis of Kopran Ltd. It's not a stock recommendation. It is at an interesting point, having formed a not so clear cup and handle pattern. It has given breakout from its 1.5 year Trendline Resistance and 50 Week SMA and 200 Week SMA. Weekly RSI has crossed above 60. Technical Analysis of Kopran Ltd. It's not a stock recommendation. It is at an interesting point, having formed a not so clear cup and handle pattern. It has given breakout from its 1.5 year Trendline Resistance and 50 Week SMA and 200 Week SMA. Weekly RSI has crossed above 60. Stock is near to BO zone with good volume build up on weekly TF and also spike on daily chart making round bottom pattern, follow chart for proper entry and exit levels. Stock is near to BO zone with good volume build up on weekly TF and also spike on daily chart making round bottom pattern, follow chart for proper entry and exit levels. Stock Name - Kopran Limited Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Price and more bu...

Kopran Ltd is engaged in pharmaceutical business. The Company's commercial enterprise units consist of Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare. It gives its merchandise in healing categories, together with anthelmintic, anti-allergic, antibiotic, cardiovascular, diabetic, gastroenterology, ache and antipyretic, and ache management, among others. The Company's bulk drugs encompass Atenolol, Amlodipine Besylate, Metoprolol Succinate, Metoprolol Tartrate, Ceftriaxone Sodium Sterile, Doripenem, Tebipenem, Roxithromycin, Rivaroxaban, Zolmitriptan, Azithromycin, Pregabalin, Lymecycline and Nitroxoline. In addition, it gives oral care, lifestyle, beauty and customized hygiene products. Its manufacturing facility is located at Khopoli, Raigad District, Maharashtra. The Company's subsidiaries consist of Kopran Research Laboratories Ltd, Kopran (H.K) Ltd and Kopran Lifesciences Ltd. #(Fig in Cr.) Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 112 140 75 128 132 143 126 117 158 149 Other Income 4 5 3 3 4 1 1 0 2 4 Total Income 116 145 78 130 136 144 126 117 160 153 Total Expenditure 91 121 66 104 105 116 112 107 146 137 Operating Profit 25 24 12 27 31 28 14 11 15 16 Interest 2 1 1 1 2 1 1 1 2 2 Depreciation 2 3 3 3 3 3 3 3 3 3 Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 Profit Before Tax 21 20 8 23 27 24 10 6 9 11 Provision for Tax 5 5 2 6 7 7 2 1 2 3 Profit ...

Overview Fii-Dii-Activity Sector Scan Sector Performance ADR/IDR Bulk & Block Deals Hot Stocks Indices Global Markets QUICK LINKS Gainers/Losers Market Commentary Upper/Lower Circuit Sensex Nifty-50 Unusual Volumes Performance Analysis Corporate Actions Event Calender Sectoral News Letter High Low • Derivatives Particulars ( Rupees In Crores.) -- -- -- -- -- Gross Sales -- -- -- -- Excise Duty -- -- -- -- Net Sales -- -- -- -- Other Operating Income -- -- -- -- Other Income -- -- -- -- Total Income -- -- -- -- Total Expenditure ** -- -- -- -- PBIDT -- -- -- -- Interest -- -- -- -- PBDT -- -- -- -- Depreciation -- -- -- -- Minority Interest Before NP -- -- -- -- Tax -- -- -- -- Deferred Tax -- -- -- -- Reported Profit After Tax -- -- -- -- Minority Interest After NP -- -- -- -- Net Profit after Minority Interest -- -- -- -- Extra-ordinary Items -- -- -- -- Adjusted Profit After Extra-ordinary item -- -- -- -- EPS (Unit Curr.) -- -- -- -- Book Value (Unit Curr.) -- -- -- -- Dividend (%) -- -- -- -- Equity -- -- -- -- Public Shareholding (Number) -- -- -- -- Public Shareholding (%) -- -- -- -- Pledged/Encumbered - No. of Shares -- -- -- -- Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- Pledged/Encumbered - % in Total Equity -- -- -- -- Non Encumbered - No. of Shares -- -- -- -- Non Encumbered - % in Total Promoters Holding -- -- -- -- Non Encumbered - % in Total Equity -- -- -- -- PBIDTM(%) -- -- -- -- PBDTM(%) -- -- -- -- PATM(%) -- -- -- -- No Record Found

Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to prod ... uce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down ...

Kopran Ltd. is a Public Limited Listed company incorporated on 26/04/1958 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1958PLC011078 and registration number is 011078. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 204.52 Cr. and Equity Capital is Rs. 48.21 Cr. for the Year ended 31/03/2022.

Overview Fii-Dii-Activity Sector Scan Sector Performance ADR/IDR Bulk & Block Deals Hot Stocks Indices Global Markets QUICK LINKS Gainers/Losers Market Commentary Upper/Lower Circuit Sensex Nifty-50 Unusual Volumes Performance Analysis Corporate Actions Event Calender Sectoral News Letter High Low • Derivatives Particulars ( Rupees In Crores.) -- -- -- -- -- Gross Sales -- -- -- -- Excise Duty -- -- -- -- Net Sales -- -- -- -- Other Operating Income -- -- -- -- Other Income -- -- -- -- Total Income -- -- -- -- Total Expenditure ** -- -- -- -- PBIDT -- -- -- -- Interest -- -- -- -- PBDT -- -- -- -- Depreciation -- -- -- -- Minority Interest Before NP -- -- -- -- Tax -- -- -- -- Deferred Tax -- -- -- -- Reported Profit After Tax -- -- -- -- Minority Interest After NP -- -- -- -- Net Profit after Minority Interest -- -- -- -- Extra-ordinary Items -- -- -- -- Adjusted Profit After Extra-ordinary item -- -- -- -- EPS (Unit Curr.) -- -- -- -- Book Value (Unit Curr.) -- -- -- -- Dividend (%) -- -- -- -- Equity -- -- -- -- Public Shareholding (Number) -- -- -- -- Public Shareholding (%) -- -- -- -- Pledged/Encumbered - No. of Shares -- -- -- -- Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- Pledged/Encumbered - % in Total Equity -- -- -- -- Non Encumbered - No. of Shares -- -- -- -- Non Encumbered - % in Total Promoters Holding -- -- -- -- Non Encumbered - % in Total Equity -- -- -- -- PBIDTM(%) -- -- -- -- PBDTM(%) -- -- -- -- PATM(%) -- -- -- -- No Record Found Co...

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958 and is headquartered in Mumbai, India. Technical Analysis of Kopran Ltd. It's not a stock recommendation. It is at an interesting point, having formed a not so clear cup and handle pattern. It has given breakout from its 1.5 year Trendline Resistance and 50 Week SMA and 200 Week SMA. Weekly RSI has crossed above 60. Technical Analysis of Kopran Ltd. It's not a stock recommendation. It is at an interesting point, having formed a not so clear cup and handle pattern. It has given breakout from its 1.5 year Trendline Resistance and 50 Week SMA and 200 Week SMA. Weekly RSI has crossed above 60. Stock is near to BO zone with good volume build up on weekly TF and also spike on daily chart making round bottom pattern, follow chart for proper entry and exit levels. Stock is near to BO zone with good volume build up on weekly TF and also spike on daily chart making round bottom pattern, follow chart for proper entry and exit levels. Stock Name - Kopran Limited Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Price and more bu...

Kopran Ltd is engaged in pharmaceutical business. The Company's commercial enterprise units consist of Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare. It gives its merchandise in healing categories, together with anthelmintic, anti-allergic, antibiotic, cardiovascular, diabetic, gastroenterology, ache and antipyretic, and ache management, among others. The Company's bulk drugs encompass Atenolol, Amlodipine Besylate, Metoprolol Succinate, Metoprolol Tartrate, Ceftriaxone Sodium Sterile, Doripenem, Tebipenem, Roxithromycin, Rivaroxaban, Zolmitriptan, Azithromycin, Pregabalin, Lymecycline and Nitroxoline. In addition, it gives oral care, lifestyle, beauty and customized hygiene products. Its manufacturing facility is located at Khopoli, Raigad District, Maharashtra. The Company's subsidiaries consist of Kopran Research Laboratories Ltd, Kopran (H.K) Ltd and Kopran Lifesciences Ltd. #(Fig in Cr.) Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 112 140 75 128 132 143 126 117 158 149 Other Income 4 5 3 3 4 1 1 0 2 4 Total Income 116 145 78 130 136 144 126 117 160 153 Total Expenditure 91 121 66 104 105 116 112 107 146 137 Operating Profit 25 24 12 27 31 28 14 11 15 16 Interest 2 1 1 1 2 1 1 1 2 2 Depreciation 2 3 3 3 3 3 3 3 3 3 Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 Profit Before Tax 21 20 8 23 27 24 10 6 9 11 Provision for Tax 5 5 2 6 7 7 2 1 2 3 Profit ...

Kopran Ltd. is a Public Limited Listed company incorporated on 26/04/1958 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1958PLC011078 and registration number is 011078. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 204.52 Cr. and Equity Capital is Rs. 48.21 Cr. for the Year ended 31/03/2022.

Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to prod ... uce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down ...